Lonza
Quick Facts: Lonza
- Signal Score
- 72.8/100 (as of 2026-11-12)
- Quality Compliance
- 86.7/100 — Clean EMA record: 3 active GMP certificates (no deductions)
- Headquarters
- Basel, Switzerland
- Modalities
- AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
- Active Programs
- 1 confirmed from ClinicalTrials.gov across 1 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Lonza
Largest CGT CDMO globally by program count.
Signal Score & Pillar Breakdown
Lonza FDA Inspection History
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2025-09-29 |
Lonza Manufacturing LLC
Vacaville, California
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2025-08-22 |
Lonza Tampa LLC
Tampa, Florida
Facility-linked
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2024-07-10 |
Lonza AG
Basel Town
Company-level
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2024-03-07 |
Lonza Biologics, Inc.
Portsmouth, New Hampshire
Company-level
|
Human Cellular, Tissue, and Gene Therapies | Not posted | Voluntary Action Indicated (VAI) |
| 2023-09-29 |
Lonza Tampa LLC
Tampa, Florida
Facility-linked
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2023-07-21 |
Lonza Biologics, Inc.
Portsmouth, New Hampshire
Company-level
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2023-03-28 |
Lonza AG
Visp
Company-level
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2022-11-04 |
Lonza AG
Basel Town
Company-level
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2022-10-13 |
Lonza Biologics Plc
Slough
Company-level
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2021-11-05 |
Lonza Walkersville, Inc.
Walkersville, Maryland
Company-level
|
Blood and Blood Products | Yes | Voluntary Action Indicated (VAI) |
| 2021-10-01 |
Lonza Tampa LLC
Tampa, Florida
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2026-02-06 |
Lonza Biologics, Inc.
Portsmouth, New Hampshire
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Lonza FDA 483 Findings 16 observations · 2021-11-05 → 2025-08-22 ?
By subsystem
By severity
- 5 — Critical: 1
- 4 — Serious: 1
- 3 — Moderate: 3
- 2 — Minor: 11
- Repeat observations: 0
Most severe findings
-
Computer control of master formula records
"Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel."
-
Lack of or inadequate process validation
"A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures."
-
In-process materials characteristics testing
"In-process materials are not tested for identity, strength, quality and purity and approved or rejected by the quality control unit during the production process and after storage for long periods."
Lonza EMA GMP Compliance 3 certificates
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| NCF-01/2025-GAL | Lonza Biologics Porrino S.L. | Spain | 2025-04-07 | COMPLIANT |
| NL/H 25/2055564A | Lonza Netherlands B.V. | Netherlands | 2025-02-20 | COMPLIANT |
| NL/H 22/2044124B | Lonza Netherlands B.V. | Netherlands | 2022-12-01 | COMPLIANT |
Lonza MHRA GMP Compliance 5 certificates
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA(IMP) 18606 Insp GMP/IMP 18606/11099-0019[I] | LONZA BIOLOGICS PLC | SLOUGH SL1 4DX | 2025-12-08 | COMPLIANT |
| UK MIA 18606 Insp GMP/IMP 18606/11099-0019[H] | LONZA BIOLOGICS PLC | SLOUGH SL1 4DX | 2025-12-08 | COMPLIANT |
| UK GMP 43108 Insp GMP 43108/9937079-0003[H] | LONZA BIOLOGICS TUAS PTE LIMITED | SG-637377 | 2016-02-22 | COMPLIANT |
| UK GMP 18606 Insp GMP 18606/835874-0005[H] | LONZA BIOLOGICS PLC | WOKINGHAM RG41 5TU | 2014-04-29 | COMPLIANT |
| UK GMP 18601 Insp GMP 18601/11093-0002[H] | LONZA BIOLOGICS | 03801 | 2010-06-14 | COMPLIANT |
Japan-accredited overseas site (PMDA)
sterile, biologics, cell and gene therapy (CGT), general (non-sterile) · 5 sites
- Visp, Switzerland · Lonza AG Visp — sterile, biologics, general (non-sterile) · valid to Aug 30, 2031
- Slough, United Kingdom · Lonza Biologics plc. — biologics · valid to Jul 19, 2031
- Houston, United States · Lonza Houston Inc. — cell and gene therapy (CGT) · valid to Apr 15, 2030
- Portsmouth, United States · Lonza Biologics Inc. — biologics · valid to Jun 21, 2031
- Vacaville, United States · Lonza Manufacturing LLC — biologics · valid to Sep 30, 2029
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Clinical Activity 1 studies
Hiring Activity 100+ open roles Beta
- There is an open site-leadership posting (Executive Director, Quality Site Head Stein, Stein, CH). Openings like this are routine and have many causes, such as a promotion, a reorganization or a new site.
- 1 posting use start-up or expansion wording in the title. Read the posting before assuming a new facility; the wording is sometimes routine.
7 mfg/ops · 6 QA/QC · 5 PD/MSAT · 6 eng. · 9 other 33
3 mfg/ops · 2 QA/QC · 1 PD/MSAT · 3 eng. · 3 other 12
· 3 QA/QC · 7 other 10
1 mfg/ops · 1 PD/MSAT · 1 eng. · 6 other 9
2 mfg/ops · 2 PD/MSAT · 1 eng. · 3 other 8
· 2 PD/MSAT · 1 eng. · 1 other 4
· 1 QA/QC · 1 eng. · 1 other 3